A5146: A PHRASE II RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF THERAPEU

A5146：评估治疗效果的 II 期随机对照试验

• 批准号: 7378415
• 负责人: TIMOTHY J. WILKIN
• 金额: $ 8.25万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378415
• 关键词: A5146; PHRASE; II; RANDOMIZED; CONTROLLED

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of A5146 is to determine whether dose modification of protease inhibitors (PIs), based on the results of therapeutic drug monitoring (TDM) to optimize PI drug concentrations, improves virologic response in PI-experienced subjects and whether such a strategy is safe and tolerable.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。A5146的目的是确定基于治疗药物监测（TDM）结果调整蛋白酶抑制剂（PI）的剂量以优化PI药物浓度是否可改善PI经历受试者的病毒学应答，以及这种策略是否安全且可耐受。